亞盛醫藥-B(06855.HK)治療白血病藥物獲美國血液學會年會"最佳研究"提名
格隆匯12月11日丨亞盛醫藥-B(06855.HK)公佈,公司在研原創新藥HQP1351的一項臨牀試驗口頭報告獲得2019年美國血液學會年會"最佳研究"提名。ASH年會是全球血液學領域規模最大、涵蓋最全面的國際學術會議,匯聚該領域最前沿的研發進展。
公告顯示,HQP1351是新型的第三代BCR-ABL酪氨酸激酶抑制劑(Tyrosine Kinase Inhibitor, TKI),用於治療對第一代、第二代TKI耐藥的慢性髓性白血病(CML)患者。HQP1351的I期研究初步結果曾於2018年ASH年會進行首次口頭彙報。
據悉,報告為HQP1351研究的安全性與初步療效的I期的結果提供了更新。HQP1351在TKI耐藥的CML患者(包括攜帶T315I突變的患者)中具有良好的耐受性,並表現出顯着且持久的抗腫瘤活性。
於公告日期,HQP1351在中國針對CP-CML和AP-CML的關鍵臨牀II期試驗病例入組已經完成。同時,該產品已在美國開展Ib期臨牀試驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.